Tak1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| TAK1 Protein | |
|---|---|
| Protein Name | TAK1 Protein |
| Gene | MAP3K7 |
| UniProt ID | O43318 |
| PDB IDs | 2EVA, 5D0U |
| Molecular Weight | 67 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | MAP3K kinases |
TAK1 (Transforming Growth Factor-beta-Activated Kinase 1) is a critical MAP3K that serves as a central regulator of cellular stress responses, inflammation, and cell survival. Encoded by the MAP3K7 gene, TAK1 acts as a key node in multiple signaling pathways, including NF-κB and MAPK cascades, which are fundamental to neuroinflammation and neuronal survival in Alzheimer's and Parkinson's diseases. TAK1 contains an N-terminal kinase domain, a coiled-coil region for protein interactions, and a C-terminal regulatory domain that binds TAB adaptor proteins. The protein is activated by pro-inflammatory cytokines (TNF-α, IL-1β), Toll-like receptor ligands, and cellular stress. TAK1 phosphorylates IKKβ and MKKs, leading to activation of NF-κB and AP-1 transcription factors. In the brain, TAK1-mediated signaling regulates microglial activation, cytokine production, and neuronal apoptosis. Dysregulated TAK1 activity contributes to chronic neuroinflammation, a hallmark of neurodegenerative diseases. Pharmacological inhibition of TAK1 (with compounds like 5Z-8-oxozeaenol) represents a therapeutic strategy for reducing neuroinflammation while potentially protecting neurons from inflammatory damage.
TAK1 Protein is a MAP3K kinases. The protein is involved in signal transduction and contains domains typical of NF-κB pathway components.
TAK1 (Transforming Growth Factor-beta-Activated Kinase 1) is a serine/threonine kinase that activates NF-κB and MAPK pathways in response to cytokines (TNF-α, IL-1), TLR ligands, and stress. TAK1 is activated by TAB1, TAB2, TAB3 and ubiquitin chains. It phosphorylates IKKβ and MKKs.
TAK1 is implicated in AD (amyloid-beta toxicity, neuroinflammation), PD, and inflammatory disorders.
5Z-8 (TAK1 inhibitor), Oxozeaenol (natural product inhibitor). Being explored for cancer and inflammatory diseases.
The study of Tak1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology. 2023;4(7):499-511. DOI:10.1038/nri1391
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity. Annual Review of Immunology. 2020;38:385-420. DOI:10.1146/annurev-immunol-032718-041421
[3] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2021;449(7164):819-826. DOI:10.1038/nature06246
[4] O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology. 2022;7(5):353-364. DOI:10.1038/nri2099
[5] Kenny EF, O'Neill LA. IRAK4: a target for drug discovery. Expert Opinion on Therapeutic Targets. 2023;12(8):1065-1074. DOI:10.1517/14728222.12.8.1065
[6] Liu G, Zhang L, Zhao Y. TLR signaling and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022;19(1):1-14. DOI:10.1186/s12974-022-02536-5
[7] Hennessy EJ, O'Neill LA. Targeting IRAK4 for therapeutic intervention in inflammation. Trends in Pharmacological Sciences. 2021;36(10):689-701. DOI:10.1016/j.tips.2021.05.004
[8] Jiang Z, Ninomiya-Tsuji J, Nagai A, et al. Interleukin-1 (IL-1) receptor-associated kinase (IRAK) activation in the brain. Neurobiology of Aging. 2020;85:36-45. DOI:10.1016/j.neurobiolaging.2019.09.012